Iovance Biotherapeutics, Inc. (IOVA) financial statements and ratios from SEC XBRL: revenue $263.50M (TTM), net margin -148.4%, revenue growth 65.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $263.50M |
| Net Margin | -148.4% |
| Revenue Growth (YoY) | 65.7% |
| EPS Growth (YoY) | -66.7% |
| FCF Growth (YoY) | -11.5% |
| Price / Book | 5.51 |
| Price / Sales | 12.48 |
| FCF Yield | -7.3% |
| Altman Z-Score | 5.28 (safe) |
| Sector P/E (Healthcare) | 21.6 |
IOVA overview · IOVA earnings · IOVA KPIs · IOVA investor relations · IOVA ownership · IOVA peers · IOVA filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.